Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Efstathios Spinos

Vascular & Interventional Radiology Richmond, VA Medical Doctor

NPI 1780630384 CMS profile 670217

2602 Buford Rd, Richmond, VA 23235

Open in the dashboard

General payments

$18,968

72 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Efstathios Spinos of Richmond, VA is reported in the CMS Open Payments database as having received $18,968 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $10,296 13
2023 General $2,115 8
2022 General $1,988 15
2021 General $1,648 3
2020 General $13 1
2019 General $2,908 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Efstathios Spinos
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Efstathios Spinos were reported at $0. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Efstathios Spinos Vascular & Interventional Radiology median Middle half National median
2019 $2,908 $422 $125–$1,555 $163
2020 $13 $200 $68–$652 $114
2021 $1,648 $280 $99–$866 $132
2022 $1,988 $433 $137–$1,497 $149
2023 $2,115 $506 $152–$2,019 $160
2024 $10,296 $556 $175–$1,930 $164
2025 $0 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. MicroVention, Inc. $17,060 38 payments
  2. Medtronic USA, Inc. $1,232 16 payments
  3. AstraZeneca Pharmaceuticals LP $148 2 payments
  4. Genentech USA, Inc. $137 1 payment
  5. Medtronic, Inc. $100 5 payments
  6. DePuy Synthes Sales Inc. $96 2 payments
  7. Medtronic Vascular, Inc. $66 1 payment
  8. Penumbra, Inc. $52 3 payments
  9. Imperative Care, INc $25 1 payment
  10. Boston Scientific Corporation $22 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,250 13 payments
  2. Travel and Lodging $3,208 15 payments
  3. Food and Beverage $2,010 43 payments
  4. Consulting Fee $1,500 1 payment
Products named General payments · program years 2019–2024
  1. WEB ANEURYSM EMBOLIZATION SYSTEM $14,175 25 payments
  2. Sofia 6F-125cm STR $1,500 1 payment
  3. WEB $1,334 9 payments
  4. Pipeline $947 5 payments
  5. SOFIA $144 1 payment
  6. HydroSoft 3D Coil $144 1 payment
  7. BRILINTA $124 1 payment
  8. OSTEOCOOL RF ABLATION $111 2 payments
  9. Solitaire $72 1 payment
  10. EMBOTRAP II Revascularization Device $71 1 payment
  11. Other $545 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

45

Median for Interventional Radiology: 38

Drug cost

$10,240

Median for Interventional Radiology: $333

Branded share of claims

100%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 24 $10,041
Clopidogrel Clopidogrel Bisulfate Brand 21 $200

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$143,980

Of which drugs: $81

Medicare patients

229

Average age 76

Services billed

989

140 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 41%
Diabetes 36%
Depression 31%
Atrial fibrillation 26%
Chronic kidney disease 26%
Osteoporosis 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 17 44 $23
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 17 23 $15
Injection, midazolam hydrochloride, per 1 mg J2250 Office 18 39 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record